Avalyn Pharma Inc. (AVLN)
NASDAQ: AVLN · Real-Time Price · USD
37.13
-1.84 (-4.72%)
Aug 20, 2026, 4:00 PM EDT - Market closed

Avalyn Pharma Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.

Total Valuation

Fiscal Year
CurrentFY 2025FY 2024
Period Ending
Aug '26 Dec '25 Dec '24
1,646--
Market Cap Growth
---
Enterprise Value
1,250--

Financial Efficiency

Fiscal Year
CurrentFY 2025FY 2024
Period Ending
Aug '26 Dec '25 Dec '24
Debt / Equity Ratio
0.040.01-
Net Debt / Equity Ratio
-0.99-1.02-1.02
Net Debt / EBITDA Ratio
3.611.502.12
Net Debt / FCF Ratio
4.031.672.44
Quick Ratio
32.769.8612.72
Current Ratio
33.1210.1913.08
Return on Equity (ROE)
--68.34%-
Return on Assets (ROA)
--41.74%-
Return on Capital Employed (ROCE)
-26.50%-67.70%-48.10%

Yields

Fiscal Year
CurrentFY 2025FY 2024
Period Ending
Aug '26 Dec '25 Dec '24
Buyback Yield / Dilution
--259.46%-
SEC Filings: 10-K · 10-Q